Although preclinical studies suggest a role for TRPV3 in skin diseases, to date, only the TRPV3 inhibitor, GRC15300 (SAR292833), by Glenmark Pharmaceuticals has progressed to clinical trials for targeting osteoarthritis and neuropathic pain. Here, TRPV3 is linked to osteoarthritis.